Selskabets formål er at drive engroshandel og distribution fortrinsvis med medicinalvarer, droger og beslægtede varer såvel i indland som i udland, herunder at have agenturer for sådanne varer. Derudover tilbydes third-party-logistics (3PL) løsninger. Selskabet kan herudover efter bestyrelsens bestemmelse beskæftige sig med anden form for handel og agenturer samt fremstilling og forarbejdning af varer.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 4.1 mia. | -51 t. | 1.3 mia. | 471.5 mio. | 238 | |
CVR: 79091812
Secondary names: K.V. TJELLESEN A/S, AKTIESELSKABET MAX JENNE, MEDICINALVARER EN GROS, TMJ A/S
Previous names: K.V. TJELLESEN A/S
1 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 36445335
CVR 67036514
CVR 20247371
CVR 36393459
CVR 37005665
Kristian Kjærsgaard left as director
Jesper Illum Lotz joined as ADM. DIR.
Mads Frydensberg Duedahl left as ADM. DIR.
Preben Møller Jørgensen left as director
The financial health of TJELLESEN MAX JENNE A/S appears to be declining, as evidenced by a drop in profitability from 19.9 million DKK in 2021 to a loss of 51,000 DKK in 2025, despite relatively stable revenue figures that peaked at 4.24 billion DKK in 2023. Equity has remained relatively stable around 471 million DKK, indicating a solid capital base, but the declining profit margins raise concerns about operational efficiency. The company operates within the wholesale trade of pharmaceuticals and medical supplies, a sector that typically demands strong financial performance, suggesting potential challenges in maintaining its competitive position. Overall, while revenue remains substantial, the recent trend in profits and the overall trajectory indicate a need for strategic adjustments to restore profitability.
AI-generated summary